Lale GULİYEVA, Ramazan ÖZDEMİR, İsmail Kürşad GÖKÇE

Supraventriküler Taşikardiye Bağlı Non-İmmun Hidrops Fetalis

Hidrops fetalis immun hidrops fetalis ve non-immun hidrops fetalis olarak iki temel grupta sınıflandırılır. Non-immun hidrops fetalis etiyolojisinde kardiyak yapısal malformasyonlar ve kardiyak aritmiler en sık (%20-25) nedenlerdendir. Fetal taşikardi iyi bilinen bir non-immunhidrops nedenidir.En sık bildirilen fetal taşikardi ise supraventriküler taşikardi (SVT) olup tüm fetal taşikardilerin %70-80’ni oluşturmaktadır. Biz bu makalede digoksin ve esmolol kombine tedavisi uygulayıp başarılı olduğumuz bir SVT’ye bağlı hidrops fetalisli yenidoğan olgusunu sunup literatürdeki tedavi protokollerini gözden geçirmek istedik.

Anahtar Kelimeler:

Digoksin, Esmolol, Hidrops fetalis, Yenidoğan supraventriküler taşikardi

Non-Immune Hydrops Fetalis Case Due To Supraventricular Tachycardia

Hydrops fetalis is classified in two main groups as immune hydrops fetalis and non-immune hydrops fetalis. Cardiac structural malformations and cardiac arrhythmias are the most common (%20-25) causes of non-immune hydrops fetalis etiology. Fetal tachycardia is a well-known cause of non-immune hydrops. The most frequently reported fetal tachycardia is supraventricular tachycardia, which is 70-80% of all fetal tachycardias. We presented a neonatal case of SVT induced hydrops fetalis with digoxin and esmolol combined treatment and reviewed the treatment protocols in the literature.

Keywords:

Digoxin, Esmolol, Hydrops fetalis, Neonatal supraventricular tachycardia,

PDF

___

1. Bellini C, Hennekam RCM, Fulcheri E, et al. Etiology of nonimmune hydrops fetalis: a systematic review. Am J Med Genet 2009; 149: 844-51.
2. Oudijk MA, Visser GH, Meijboom EJ. Fetal Tachyarrhythmia – Part 1: Diagnosis. Indian Pacing Electrophysiol J 2004; 4: 104
3. Norton ME. Nonimmune hydrops fetalis. Semin Perinatol 1994; 18: 321–332.
4. Ayida GA, Soothil PW, Rodeck CH. Survival in non-immune hydropsfetalis without malformation of chromosomal abnormalities after invasive treatment. Fetal Diagn Ther 1995; 10: 101–105
5. Moak JP. Supraventricular tachycardia in the neonate and infant. Prog Pediatr Cardiol 2000; 11: 25-38.
6. Lewis L, Poojari G, Sanoj KM, Kamath SP, Kachane YP. Neonatal arrhythmia with diaphragmatic eventration. Indian J Pediatr 2008; 75: 1083-5.
7. De Giovanni JV, Dindar A, Griffith MJ, et al. Recovery pattern of left ventricular dysfunction following radiofrequency ablation of incessant supraventricular tachycardia in infants and children. Heart 1998; 79: 588-92.
8. Murphy JH. Nonimmune hydrops fetalis. Neo Reviews 2004; 5: 5-14.
9. Hrtánková M, Biringer K, Siváková J, Šumichrastová P, Lukáč P, Danko J. Fetal magnetocardiography: a promising way to diagnose fetal arrhytmia and to study fetal heart rate variability? Ceska Gynekol 2015; 80: 58-63.
10. Kothari DS, Skinner JR. Neonatal tachycardias: an update. Arch Dis Child Fetal Neonatal Ed 2006; 91: 136-44.
11. Cuneo BF, Strasburger JF. Management strategy for fetal tachycardia. Obstet Gynecol 2000; 96: 575-81.
12. Van Hare GF. Neonatal arrhythmias. In: Fanaroff AA, Martin RJ (eds). Neonatal Perinatal Medicine Diseases of the Fetus and Infant (7th ed). St. Louis: Mosby, 2002: 1150- 63.
13. Oudijk MA, Visser GH, Meijboom EJ. Fetal tachyarrhythmia - Part 1Fetal Tachyarrhythmia - Part II: Treatment. Electrophysiol J 2004; 4: 185-94.
14. Merriman JB, Gonzalez JM, Rychik J. Can digoxin and sotalol therapy for fetal supraventricular tachycardia and hydrops be successful? A case report. J Reprod Med 2008; 53: 357-9.
15. Akdeniz C, Kıplapınar M, Şengül FS, Tuzcu V. Antiaritmik tedaviye cevapsız supraventriküler taşikardili yenidoğanda katater ablasyonu ile tedavi. Anadolu Kardiyoloji Dergisi 2012; 12: 1-3.
16. Ceviz N, Çeliker A. Çocuklarda görülen aritmilerin farmakolojik tedavisi. Türk Aritmi Pacemaker ve Elektrofizyoloji Dergisi 2005; 3: 173-87.
17. Etches P, Demianczuk N, Chari R. Nonimmune hydropsfetalis. In: Rennie JM, editor. Roberton’s Textbook of Neonatology. 4th ed. Philadelphia: Elsevier Churchill Livingstone. 2005: 773-84.